Company Overview and News

28
Your Daily Pharma Scoop: Kamada Phase 3 Approved, Vivus Positive, IsoRay Down

2018-07-12 seekingalpha
CHMP on board with design of late-stage study of Kamada's inhaled AAT for AATD; shares up 4% premarket
VVUS RSLS MNOV SUMM MGEN ISR KMDA SMMT ACHN SCYX

1
MGEN / Miragen Therapeutics 8-K (Current Report)

2018-07-10 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

60
10 Top Stock Ideas to Beat the Blues

2018-07-06 investorplace
The market isn’t looking cheery right now. In between choppy trading conditions and market pullbacks, who knows where to turn for the remaining half of 2018? However, there are still gems to be found. You just have to be more selective, and more active in your research.
WFCNP FB ALB WFC.PRL MGEN WFC.PRJ WFC.PRT TWLO WFC.PRR WFC.PRQ WFC.PRP WFC.PRO WFC.PRN WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS NBL AIMT ZAYO HIIQ BABA S

44
MGEN / Miragen Therapeutics 8-K (Current Report)

2018-06-28 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

44
MGEN / Miragen Therapeutics 8-K (Current Report)

2018-06-04 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

43
Miragen Therapeutics to Present First Cobomarsen Phase 1 Clinical Trial Data From Patients With Adult T-Cell Leukemia/lymphoma and New Interim Data From Patients With Mycosis Fungoides at the 2018 American Society of Clinical Oncology Annual Meeting

2018-06-04 globenewswire
BOULDER, Colo., June 04, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced the first observations on the safety and efficacy of cobomarsen in adult T-cell leukemia/lymphoma (ATLL) patients, a highly morbid T-cell malignancy seen in patients previously infected with the human T-lymphotropic virus type 1 (HTLV1).
MGEN

43
MGEN / Miragen Therapeutics null

2018-05-22 sec.gov
begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,2]3(#,X/CYS=')E86T-"FC>[email protected][email protected]
MGEN

43
miRagen Therapeutics to Present New Interim Data From Phase 1 Clinical Trial of Cobomarsen at the 2018 American Society of Clinical Oncology Annual Meeting

2018-05-16 globenewswire
BOULDER, Colo., May 16, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced today that new interim data from its ongoing Phase 1 clinical trial of cobomarsen (also known as MRG-106) in patients with the mycosis fungoides form of cutaneous T-cell lymphoma (CTCL) will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting.
MGEN

43
MGEN / Miragen Therapeutics DEF 14A

2018-05-15 sec.gov
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MGEN

45
MGEN / Miragen Therapeutics DEFA14A

2018-05-15 sec.gov
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

43
miRagen Therapeutics' (MGEN) CEO William Marshall on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Good afternoon everyone, and welcome to the miRagen Therapeutics First Quarter 2018 Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. And as a reminder, today's call is being recorded.
MGEN

45
MGEN / Miragen Therapeutics 10-Q (Quarterly Report)

2018-05-09 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
MGEN

43
MGEN / Miragen Therapeutics FORM 8-K (Current Report)

2018-05-09 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

45
MGEN / Miragen Therapeutics FORM 8-K (Current Report)

2018-05-08 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
MGEN

44
miRagen Therapeutics Announces New Interim Data From Phase 1 Clinical Trial of Cobomarsen in Mycosis Fungoides

2018-05-08 globenewswire
BOULDER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, announced new interim data from its Phase 1 clinical trial of cobomarsen in patients with the mycosis fungoides (MF) form of cutaneous T-cell lymphoma (CTCL). The data will be presented May 9, 2018, at the “2015.
MGEN

Related Articles

CYTX: Cytori Therapeutics Analysis and Research Report

9h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

Silicon Investor Message Boards

This table lists all message boards related to MGEN / Miragen Therapeutics on message board site Silicon Investor.

Amgen Inc. (AMGN) Micro General Corp. OTCBB: MGEN
planet 411.com (formerly ComGen CGEE) ComGen Corp (CGEE)
AMGEN
CUSIP: 60463E103